Publications by authors named "Samuel H Lim"
Background And Aims: Despite intravenous (IV) vedolizumab being established for treatment of inflammatory bowel disease (IBD), the novel subcutaneous (SC) route of administration may provide numerous incentives to switch. However, large-scale real-world data regarding the long-term safety and effectiveness of this strategy are lacking.
Methods: IBD patients on IV vedolizumab across 11 UK sites agreed to transition to SC injections or otherwise continued IV treatment.
Article Synopsis
- The study examines the effectiveness of sequential drug treatments for ulcerative colitis (UC), specifically comparing the use of vedolizumab (VDZ) and anti-TNF therapies as second-line treatments.
- Researchers analyzed data from patients who switched treatments between May 2013 and August 2020, looking at various health outcomes over a 52-week period.
- Results indicated that patients receiving VDZ after anti-TNF had significantly better treatment persistence, colectomy-free survival, and clinical remission compared to those receiving anti-TNF after VDZ, suggesting a favorable effect of the treatment order on patient outcomes.
Cytokinesis requires the cooperation of many cytoskeletal and membrane regulators. Most of the major players required for cytokinesis are known, but the temporal regulation and adaptations for different cell types are less understood. KIF20B (previously called MPHOSPH1 or MPP1) is a member of the Kinesin-6 family, which also includes the better-known members KIF23/MKLP1 and KIF20A/MKLP2.
View Article and Find Full Text PDF